Drug intelligence / Profile preview

Universal COVID vaccine

Development stage: Unknown
Lead developer: Dx&Vx
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous, Oral, Intranasal, Inhalation, Transdermal

Overview

DX-DRG-B05 is a Universal COVID vaccine developed by Dx&Vx. It is designed to induce both antibodies for the prevention of COVID-19 and immune cells that eliminate the virus. The vaccine employs a novel approach, described as a corona virus-like particle vaccine, to achieve this dual immune response.

Other names: Corona virus like particle vaccine

Beyond the preview

Go deeper on Universal COVID vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Universal COVID vaccine.

Explore the full profile